Patients' attitudes toward deprescribing and their experiences communicating with clinicians and pharmacists.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY Therapeutic Advances in Drug Safety Pub Date : 2022-08-19 eCollection Date: 2022-01-01 DOI:10.1177/20420986221116465
Kaylee M Lukacena, James W Keck, Patricia R Freeman, Nancy Grant Harrington, Mark J Huffmyer, Daniela C Moga
{"title":"Patients' attitudes toward deprescribing and their experiences communicating with clinicians and pharmacists.","authors":"Kaylee M Lukacena,&nbsp;James W Keck,&nbsp;Patricia R Freeman,&nbsp;Nancy Grant Harrington,&nbsp;Mark J Huffmyer,&nbsp;Daniela C Moga","doi":"10.1177/20420986221116465","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Developing effective deprescribing interventions relies on understanding attitudes, beliefs, and communication challenges of those involved in the deprescribing decision-making process, including the patient, the primary care clinician, and the pharmacist. The objective of this study was to assess patients' beliefs and attitudes and identify facilitators of and barriers to deprescribing.</p><p><strong>Methods: </strong>As part of a larger study, we recruited patients ⩾18 years of age taking ⩾3 chronic medications. Participants were recruited from retail pharmacies associated with the University of Kentucky HealthCare system. They completed an electronic survey that included demographic information, questions about communication with their primary care clinician and pharmacists, and the revised Patients' Attitudes Toward Deprescribing (rPATD) questionnaire.</p><p><strong>Results: </strong>Our analyses included 103 participants (<i>n</i> = 65 identified as female and <i>n</i> = 74 as White/Caucasian) with a mean age of 50.4 years [standard deviation (SD) = 15.5]. Participants reported taking an average of 8.4 daily medications (SD = 6.1). Most participants reported effective communication with clinicians and pharmacists (66.9%) and expressed willingness to stop one of their medications if their clinician said it was possible (83.5%). Predictors of willingness to accept deprescribing were older age [odds ratio (OR) = 2.99, 95% confidence interval (CI) = 1.45-6.2], college/graduate degree (OR = 55.25, 95% CI = 5.74-531.4), perceiving medications as less appropriate (OR = 8.99, 95% CI = 1.1-73.62), and perceived effectiveness of communication with the clinician or pharmacist (OR = 4.56, 95% CI = 0.85-24.35).</p><p><strong>Conclusion: </strong>Adults taking ⩾3 chronic medications expressed high willingness to accept deprescribing of medications when their doctor said it was possible. Targeted strategies to facilitate communication within the patient-primary care clinician-pharmacist triad that consider patient characteristics such as age and education level may be necessary ingredients for developing successful deprescribing interventions.</p><p><strong>Plain language summary: </strong><b>Are patients willing to accept stopping medications?</b> Sometimes, medicines that a patient takes regularly become inappropriate. In other words, the risks of adverse effects might be greater than a medicine's potential benefits. The decision to stop such medicines should involve the patient and consider their preferences. We surveyed a group of patients taking multiple medicines to see how they felt about having those medicines stopped. We also asked patients whether and how much they talk to their primary care clinician and pharmacists about their medicines. To qualify for this study, patients had to be at least 18 years old and to take three or more medicines daily; they also needed to speak English. Participants provided demographic information and answered questions about their medicines, their communication with primary care clinicians and pharmacists, and their feelings about having one or more of their medicines stopped. We recruited 107 people and were able to use responses from 103 of them. Their average age was 50 years; 65 of them identified as female, and 75 identified as White/Caucasian. Most of our participants mentioned having conversations with primary care clinicians and pharmacists and said they would be willing to stop a medication if their clinician said it was possible. Older participants, those with more years of education, those who thought their medications might lead to side effects, and those who communicated with their clinician or pharmacists were more willing to have one of their medicines stopped.Our results indicate that patient characteristics and communication with clinicians and pharmacists are factors to consider when designing interventions to reduce the use of inappropriate medicines.</p>","PeriodicalId":23012,"journal":{"name":"Therapeutic Advances in Drug Safety","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2022-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/76/6b/10.1177_20420986221116465.PMC9393353.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420986221116465","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 3

Abstract

Purpose: Developing effective deprescribing interventions relies on understanding attitudes, beliefs, and communication challenges of those involved in the deprescribing decision-making process, including the patient, the primary care clinician, and the pharmacist. The objective of this study was to assess patients' beliefs and attitudes and identify facilitators of and barriers to deprescribing.

Methods: As part of a larger study, we recruited patients ⩾18 years of age taking ⩾3 chronic medications. Participants were recruited from retail pharmacies associated with the University of Kentucky HealthCare system. They completed an electronic survey that included demographic information, questions about communication with their primary care clinician and pharmacists, and the revised Patients' Attitudes Toward Deprescribing (rPATD) questionnaire.

Results: Our analyses included 103 participants (n = 65 identified as female and n = 74 as White/Caucasian) with a mean age of 50.4 years [standard deviation (SD) = 15.5]. Participants reported taking an average of 8.4 daily medications (SD = 6.1). Most participants reported effective communication with clinicians and pharmacists (66.9%) and expressed willingness to stop one of their medications if their clinician said it was possible (83.5%). Predictors of willingness to accept deprescribing were older age [odds ratio (OR) = 2.99, 95% confidence interval (CI) = 1.45-6.2], college/graduate degree (OR = 55.25, 95% CI = 5.74-531.4), perceiving medications as less appropriate (OR = 8.99, 95% CI = 1.1-73.62), and perceived effectiveness of communication with the clinician or pharmacist (OR = 4.56, 95% CI = 0.85-24.35).

Conclusion: Adults taking ⩾3 chronic medications expressed high willingness to accept deprescribing of medications when their doctor said it was possible. Targeted strategies to facilitate communication within the patient-primary care clinician-pharmacist triad that consider patient characteristics such as age and education level may be necessary ingredients for developing successful deprescribing interventions.

Plain language summary: Are patients willing to accept stopping medications? Sometimes, medicines that a patient takes regularly become inappropriate. In other words, the risks of adverse effects might be greater than a medicine's potential benefits. The decision to stop such medicines should involve the patient and consider their preferences. We surveyed a group of patients taking multiple medicines to see how they felt about having those medicines stopped. We also asked patients whether and how much they talk to their primary care clinician and pharmacists about their medicines. To qualify for this study, patients had to be at least 18 years old and to take three or more medicines daily; they also needed to speak English. Participants provided demographic information and answered questions about their medicines, their communication with primary care clinicians and pharmacists, and their feelings about having one or more of their medicines stopped. We recruited 107 people and were able to use responses from 103 of them. Their average age was 50 years; 65 of them identified as female, and 75 identified as White/Caucasian. Most of our participants mentioned having conversations with primary care clinicians and pharmacists and said they would be willing to stop a medication if their clinician said it was possible. Older participants, those with more years of education, those who thought their medications might lead to side effects, and those who communicated with their clinician or pharmacists were more willing to have one of their medicines stopped.Our results indicate that patient characteristics and communication with clinicians and pharmacists are factors to consider when designing interventions to reduce the use of inappropriate medicines.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
患者对处方的态度及与临床医师、药师沟通的体会。
目的:制定有效的处方解除干预措施依赖于理解态度、信念和参与处方解除决策过程的人员的沟通挑战,包括患者、初级保健临床医生和药剂师。本研究的目的是评估患者的信念和态度,并确定处方的促进因素和障碍。方法:作为更大研究的一部分,我们招募了服用小于或等于18岁的慢性药物的患者。参与者是从肯塔基大学医疗保健系统相关的零售药店招募的。他们完成了一项电子调查,包括人口统计信息、与初级保健临床医生和药剂师沟通的问题,以及修订后的患者对处方减少的态度问卷。结果:我们的分析包括103名参与者(n = 65名女性,n = 74名白人/高加索人),平均年龄为50.4岁[标准差(SD) = 15.5]。参与者报告平均每天服用8.4种药物(SD = 6.1)。大多数参与者报告与临床医生和药剂师进行了有效的沟通(66.9%),如果临床医生说可能的话,他们表示愿意停药(83.5%)。接受处方减少意愿的预测因子为年龄较大[比值比(OR) = 2.99, 95%可信区间(CI) = 1.45-6.2]、大学/研究生学历(OR = 55.25, 95% CI = 5.74-531.4)、感觉用药不合适(OR = 8.99, 95% CI = 1.1-73.62)、感觉与临床医生或药剂师沟通的有效性(OR = 4.56, 95% CI = 0.85-24.35)。结论:服用小于或等于3种慢性药物的成年人在医生说可能的情况下表达了接受药物处方的高度意愿。有针对性的策略,以促进沟通在病人-初级保健医生-药剂师三位一体,考虑病人的特点,如年龄和教育水平可能是必要的成分开发成功的处方干预。简明扼要:患者是否愿意接受停药?有时,病人经常服用的药物会变得不合适。换句话说,副作用的风险可能大于药物的潜在益处。停药的决定应由患者参与,并考虑他们的偏好。我们调查了一组服用多种药物的病人,看看他们停药后的感受。我们还询问患者是否和他们的初级保健临床医生和药剂师谈论他们的药物,以及谈论了多少。为了符合这项研究的资格,患者必须年满18岁,每天服用三种或更多药物;他们还需要说英语。参与者提供了人口统计信息,并回答了有关他们的药物、他们与初级保健临床医生和药剂师的沟通以及他们对一种或多种药物被停药的感受的问题。我们招募了107人,并使用了其中103人的回答。他们的平均年龄为50岁;其中65人是女性,75人是白人或高加索人。我们的大多数参与者都提到了与初级保健临床医生和药剂师的对话,并表示如果他们的临床医生说这是可能的,他们愿意停药。年龄较大的参与者、受教育年限较高的参与者、认为药物可能导致副作用的参与者、以及与临床医生或药剂师沟通的参与者更愿意停止服用其中一种药物。我们的研究结果表明,在设计干预措施以减少不适当药物的使用时,患者特征和与临床医生和药剂师的沟通是需要考虑的因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety Medicine-Pharmacology (medical)
CiteScore
6.70
自引率
4.50%
发文量
31
审稿时长
9 weeks
期刊介绍: Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.
期刊最新文献
Determining the optimum dose of remifentanil in combination with propofol for total intravenous anaesthesia in hysteroscopy under Narcotrend and SPI monitoring. The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey. Comparison of a single intravenous infusion of alfentanil or sufentanil combined with target-controlled infusion of propofol for daytime hysteroscopy: a randomized clinical trial. Governance of artificial intelligence and machine learning in pharmacovigilance: what works today and what more is needed? Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug-supplement interaction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1